In another study, treatment with a combination drug, lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals, Boston, MA, USA), showed improved lung function and nutritional status as well as decreased pulmonary exacerbations in CF patients with severe lung disease caused by homozygous F508del CFTR mutations who were 12 years of age or older [33,34]. The gene discussed is CFTR; the disease is cystic fibrosis.